Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance

Institutions Authors Share
Ludwig Center at Stanford, United States of America (USA)
12.000000
12.000000
0.86
Ben-Gurion University of the Negev (BGU), Israel
1.000000
0.07
Stanford Medicine, United States of America (USA)
1.000000
0.07